{"nctId":"NCT01709084","briefTitle":"A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment","startDateStruct":{"date":"2013-10-02","type":"ACTUAL"},"conditions":["Human Immunodeficiency Virus-type 1 Infection"],"count":426,"armGroups":[{"label":"Group 1","type":"EXPERIMENTAL","interventionNames":["Drug: Rilpivirine","Drug: Tenofovir disoproxil fumarate","Drug: Emtricitabine"]},{"label":"Group 2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Efavirenz","Drug: Tenofovir disoproxil fumarate","Drug: Emtricitabine"]}],"interventions":[{"name":"Rilpivirine","otherNames":["EDURANT"]},{"name":"Efavirenz","otherNames":[]},{"name":"Tenofovir disoproxil fumarate","otherNames":[]},{"name":"Emtricitabine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nDocumented human immunodeficiency virus-type 1 (HIV-1) infection Patients who have been receiving first line highly active antiretroviral therapy (HAART) for at least 1 year before the screening visit Patients who have been taking the same ARV combination for at least 8 weeks before the screening visit and are expected to continue on this regimen throughout the screening period.\n\nPatients who prefer to change the current HAART regimen for reasons of simplification and/or toxicity of nucleoside/nucleotide reverse transcriptase inhibitor (N\\[t\\]RTI) Plasma HIV-1 RNA less than 50 copies per mL and CD4+ cell count higher than 200 per mm3 at the screening visit Agrees to protocol-defined use of effective contraception\n\nExclusion Criteria:\n\nHistory of virologic failure (2 consecutive plasma HIV-1 ribonucleic acid (RNA) more than or equal to 400 copies per mL) while on previous or current ART History of immunologic failure (2 consecutive CD4+ cell counts during HAART treatment falling below the pre-HAART level) History of any primary N\\[t\\]RTI or NNRTI mutations Has a previously documented HIV-2 infection Significantly decreased hepatic function or hepatic insufficiency or diagnosed with acute clinical viral hepatitis Diagnosed with Mycobacterium tuberculosis infection Severe laboratory abnormalities Creatinine clearance less than 50 mL per minute Addicted to drug, including alcohol or recreational drugs","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Plasma Human Immunodeficiency Virus - Type 1 Ribonucleic Acid (HIV-1 RNA) Levels Less Than (<) 400 Copies Per Milliliter (Copies/mL) at Week 48","description":"Percentage of Participants with viral load (plasma HIV-1 RNA levels) less than 400 copies per mL at Week 48, obtained by the modified Food and Drug Administration (FDA) Snapshot method.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.9","spread":null},{"groupId":"OG001","value":"96.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Plasma HIV-1 RNA Levels < 50 Copies/mL at Week 48","description":"Percentage of Participants with plasma HIV-1 RNA \\<50 copies/mL, obtained by the modified Food and Drug Administration (FDA) Snapshot method.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.9","spread":null},{"groupId":"OG001","value":"96.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Plasma HIV-1 RNA Levels More Than or Equal to (>=) 400 Copies/mL at Week 48 Based on Time to Loss of Virologic Response (TLOVR) [Non-virologic Failure Censored] Imputation Method.","description":"Percentage of participants with plasma HIV-1 RNA levels analysed based on time to loss of virologic response (TLOVR) imputation method which is defined as confirmed plasma HIV-1 RNA \\>=400 copies/mL, excluding participants who discontinued the study with HIV-1 RNA suppression \\<400 copies/mL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Plasma HIV-1 RNA Levels >= 50 Copies Per Milliliter (Copies/mL) at Week 48 Based on Time to Loss of Virologic Response (TLOVR) [Non-virologic Failure Censored] Imputation Method.","description":"Percentage of participants with plasma HIV-1 RNA levels analysed based on TLOVR imputation method which is defined as confirmed plasma HIV-1 RNA \\>=50 copies/mL, excluding participants who discontinued the study with HIV-1 RNA suppression \\<50 copies/mL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participant With Treatment Adherence Based on Tablet Count","description":"In both treatment groups adherence rates assessed by tablet count, the majority of participants had an adherence of \\>95% (97% and 98% in RPV and EFV treated treatment groups respectively).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.2","spread":"1.981"},{"groupId":"OG001","value":"97.6","spread":"1.649"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-Emergent Nucleoside Reverse Transcriptase Inhibitor (N[t]RTI) or Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (NNRTI) Mutations","description":"To compare the loss of treatment options, the number of participants with treatment-emergent N\\[t\\]RTI or NNRTI mutations, as defined by IAS-USA (2014), after virologic failure were compared between the treatment groups.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":213},"commonTop":["Upper Respiratory Tract Infection","Headache","Urinary Tract Infection","Back Pain","Malaria"]}}}